Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
1392756 | European Journal of Medicinal Chemistry | 2013 | 5 Pages |
•Peptidic water-soluble inhibitors incorporating imidazolium scaffold are reported.•Inhibition was extremely sensitive to modifications of the imidazolium moieties.•Various modulations suggested a bent conformation for the active inhibitors.•Enzyme inhibition is reported for both tissue transglutaminase and factor.
New peptidic water-soluble inhibitors are reported. In addition to the carboxylate moiety, a new polar warhead was explored. Depending on the size of its substituents, the newly appended imidazolium scaffold designed to enhance the hydrophilic character of the inhibitors could induce a good inhibition for tissue transglutaminase (TG2) and blood coagulation factor XIIIa (FXIIIa). Correlated with the narrow tunnel that hosts the target catalytic cysteine residue, the various modulations suggest a bent conformation of the ligands as the binding pattern mode. Analogues in the dialkylsulfonium series were also tested and showed specificity for TG2 over FXIIIa.
Graphical abstractFigure optionsDownload full-size imageDownload as PowerPoint slide